Figure 1From: Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patientsOverall survival by treatment strategy. The OS is similar in patients who were treated with azacitidine (N = 26) and intensive chemotherapy (IC; N = 90), and is worse in patients who received BSC (N = 97).Back to article page